AKT I 1,2
Akt-I-1,2 inhibited both Akt1 and Akt2 with IC50 values of 2.7 and 21 microM respectively. Biochem J. 2005 Jan 15;385(Pt 2):399-408.<BP> The compound did not inhibit Akt3 nor mutants lacking the PH (pleckstrin homology) domain at concentrations up to 250 microM. The compoundis areversible inhibitor, and exhibits a linear mixed-type inhibition against ATP and peptide substrate. In addition to inhibiting kinase activity of individual Akt isoforms, both inhibitors (AKT-I-1 & AKT-I-1,2)blocked the phosphorylation and activation of the corresponding Akt isoforms by PDK1 (phosphoinositide-dependent kinase 1). | |
新西兰Symansis公司是新西兰一家发展抗体作为新药开发中细胞讯息传递研究工具的公司。
Symansis公司新推出Multi-Kinase ELISA Arrays试剂盒，采用特异的抗磷酸化激酶抗体和ELISA反应原理，使磷酸化激酶的检测变得简单。一次操作，可同时检测多个磷酸化激酶，避免了传统的Western blot方法需要分开操作及其一系列复杂繁琐的操作和等待。其酶抑制剂产品如下：
AKT AKt-I-1 SY AKT-I-1
AMPK A-769662 SY-A-769662
AUR (CDK) JNJ7706621 SY- JNJ7706621
Aurora VX-680 SY- VX-680
Bcl-2 ABT-737 SY- ABT-737
BCR-ABL Imatinib mesylate SY- Imatinib mesylate
BCR-ABL PD173955 SY-PD173955
CDK AT-7519 SY- AT-7519
CDK SNS-032 SY- SNS-032
EGFR Gefitinib SY- Gefitinib
EGFR Erlotinib SY- Erlotinib
本网站将在规定时间内给予删除等相关处理。
